Related Experiment Video
Updated: Jun 2, 2026
Moving Upwards: A Simple and Flexible In Vitro Three-dimensional Invasion Assay Protocol
Published on: March 12, 2018
An in vitro chemosensitivity test for solid human tumors using collagen gel droplet embedded cultures
H Kobayashi1, K Tanisaka, O Doi
1OSAKA MED CTR & CARDIOVASC DIS,DEPT THORAC SURG,HIGASHINARI KU,OSAKA 537,JAPAN. OSAKA MED CTR & CARDIOVASC DIS,DEPT NEUROSURG,HIGASHINARI KU,OSAKA 537,JAPAN. KITANO HOSP,TAZUKE KOFUKAI MED RES INST,DEPT THORAC SURG,KITA KU,OSAKA 530,JAPAN. KINKI UNIV,SCH MED,DEPT SURG 1,OSAKAYAMA,OSAKA 589,JAPAN. TEIKYO UNIV,SCH MED,DEPT SURG 1,ITABASHI KU,TOKYO 173,JAPAN. TOCHIGI CANC CTR,DEPT SURG,UTSUNOMIYA,TOCHIGI 320,JAPAN. KEIO UNIV,SCH MED,DEPT SURG,SHINJUKU KU,TOKYO 160,JAPAN.
Abstract:
In vitro chemosensitivity testing using a collagen gel droplet embedded culture drug sensitivity test (CD-DST), was conducted with several types of solid cancer. The overall evaluable rate was 80% (443/554), including 76% for lung (n=243), 78% for breast (n=110), 87% for gastric (n=62), 83% for colorectal (n=107) cancers and 88% for 32 metastatic brain tumors. The in vitro sensitivity of breast, gastric and colorectal cancers to mitomycin C (MMC), cisplatin (CDDP), 5-fluorouracil (5-FU) and doxorubicin (DXR) was similar to the efficacy rates reported for each drug. This was also observed with lung cancer, the sensitivity of which to MMC, CDDP, vindesine (VDS) and etoposide (VP-16) was similar to the clinical efficacy. The clinical response to chemotherapy was compared with the results of in vitro chemosensitivity testing in Il patients: the clinical correlation was 91%, with a 80% true positive and 100% true negative rate. These results suggest that the CD-DST may be clinically useful by allowing the prediction of clinical response in various solid cancers.
